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Abstract
Introduction and hypothesis The objective of this study was
to evaluate the efficacy and safety of the Miniarc Precise®
single-incision sling (American Medical Systems,
Minnetonka, MN, USA) placed at the time of a robotic
sacrocolpopexy.
Methods This was a prospective study of a single-incision
suburethral sling placed at the time of robotic sacrocolpopexy
in women with stress urinary incontinence (SUI) and pelvic
organ prolapse. Primary outcome measure was cure at 1 year,
defined objectively by a negative cough stress test (CST) and
subjectively by a score of “0 or 1” on question 17 of the Pelvic
Floor Distress Inventory (PFDI-20): “Do you experience urine
leakage related to coughing/sneezing/laughing?” Secondary
outcome measures included the change in Urinary Distress
Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7)
scores at 1 year. All sling-related complications were reported.
Paired Student’s t test and the Wilcoxon signed-rank test were
used for statistical analysis.
Results One hundred and one patients were included between
August 2010 and July 2012. One-year follow-up was avail-
able for 97 out of 101 patients (96 %). Objective cure was
90 % and subjective cure was 87 %. Baseline UDI-6 scores
improved from 34.8±25.1 to 6.7±11.2 at 1 year (p<0.001).
Similarly, UIQ-7 scores improved from 21.1±22.8 to 2.4±
8.2 at 1 year (p<0.001). There were no intraoperative
cystotomies, no mesh erosions, no sling revisions, and no
cases of urinary retention. The retreatment rate for persistent
SUI was 8 % (8 out of 97).
Conclusions The addition of a single-incision suburethral
sling at the time of robotic sacrocolpopexy in women with
SUI resulted in an 87 % cure rate at 1 year.
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Introduction
Stress urinary incontinence (SUI) is a common condition
that affects up to 35 % of women above the age of 50 [1].
The majority of women presenting with pelvic organ pro-
lapse have coexisting SUI [2]. Furthermore, prolapse repair
is associated with new onset stress incontinence in a large
proportion (up to 40 %) of previously continent patients [3,
4]. The Colpopexy and Urinary Reduction Efforts (CARE)
trial concluded that the routine addition of Burch
colposuspension to abdominal sacrocolpopexy significantly
decreased the incidence of de novo SUI [3]. Similar results
were shown with the placement of a suburethral sling at the
time of prolapse repair in the Outcomes Following Vaginal
Prolapse and Midurethral Sling (OPUS) trial [4].
Retropubic suburethral slings are associated with some
risk of retropubic hematoma, bladder and bowel perfora-
tion, urinary retention, and long-term voiding dysfunc-
tion; including urgency, frequency, and incomplete blad-
der emptying [5, 6]. The risk of developing these symp-
toms may be higher in patients with preoperative obstruc-
tive voiding. Alternatively, transobturator slings offered a
lower rate of the above-mentioned complications, but
have added the risks of inner thigh pain, vaginal sulci
pain, and mesh exposure [7–9]. Single-incision slings
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were developed to further reduce sling-related complica-
tions; unfortunately, their efficacy has been questioned
owing to less than desirable results in early trials [10].
However, single-incision slings have different designs and
anchoring mechanisms and would be expected to have
different success rates. The FDA’s 2013 publication:
“Considerations about surgical mesh for SUI” stated that
“Additional studies may help the agency to better under-
stand the safety and effectiveness of these (mini-slings)
devices” [11].
A well-conducted, single-arm, multicenter prospective
study evaluated the Miniarc Precise® single-incision sling
(American Medical Systems, Minnetonka, MN, USA) and
found it to be highly efficacious (80 % objective cure) with
a low complication rate [12].
Prior studies focused on the efficacy of the single-incision
sling as a standalone therapy for isolated SUI. The literature
is sparse regarding single-incision sling placement at the
time of prolapse repair and there are no studies specifically
evaluating the Miniarc Precise® single-incision sling at the
time of robotic sacrocolpopexy.
At our center, one of the attending surgeons (C.S.) started
offering the Miniarc Precise® single-incision suburethral
sling to the majority of patients with pelvic organ prolapse
undergoing a robotic sacrocolpopexy. The objective of this
study was to prospectively assess the 1-year outcomes of the
Miniarc Precise® single-incision suburethral sling placed at
the time of robotic sacrocolpopexy.
Materials and methods
This was a prospective study, approved by the Atlantic Health
Institutional Review Board (R12-09-001) and listed on www.
clinicaltrials.gov (NCT01982188). The study included all con-
secutive patients who underwent placement of a single-incision
suburethral sling (Miniarc Precise®, by American Medical
Systems, Minnetonka, MN, USA) at the time of robotic
sacrocolpopexy. Inclusion criteria were stage II to IV pelvic
organ prolapse and a positive reduction cough stress test (CST)
in women with or without a complaint of urinary incontinence.
Patients with previous surgery for SUI were excluded from the
study. At the conclusion of the robotic sacrocolpopexy, the sling
was placed through a 2-cm vertical suburethral vaginal incision.
Midurethral tunnels were created bilaterally following the same
trajectory as a transobturator sling dissection and the sling was
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Fig. 1 Flowchart of patients
Table 1 Baseline demographic data (N=101)
Characteristic Data
Age (years) mean ± SD 56.5±9.8
BMI (mean ± SD) 26.5±5.1
Vaginal parity (median) 2
Postmenopausal (%) 61.4
Smoker (%) 8
Subjective preoperative urgency (%) 59
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inserted aiming toward the notch under the ipsilateral adductor
longus tendon. The anchoring tip rested in the internal obturator
muscle at its insertion site into the pubic ramus without travers-
ing the obturator membrane or any of the inner thigh muscles.
The sling mesh laid flat against the mid-urethra without tension
or any intervening space.
Outcome measures were evaluated at baseline and 1 year
postoperatively. Baseline demographics included age, BMI,
prior surgical and obstetrical history, and menopausal status.
Objective measures included pelvic organ prolapse quantifi-
cation (POPQ) examination and a CST with prolapse reduc-
tion using Proctoswabs at the time of baseline multi-channel
urodynamic testing. The CST challenge was performed with
250 ml in the bladder. Additionally, Valsalva and cough leak
point pressures (LPP) were collected. For the postoperative
voiding trials, all Foleys were removed early in the morning
and the patient’s voids were measured and reported to the
surgeon who would decide to send the patient home with or
without a catheter. The decision is based on the voided vol-
umes (a minimum of 200 ml), the time interval since Foley
removal or last void, occasional use of a bladder scanner, and
the patient’s report of feeling that her bladder was empty.
Subjective measures included the urinary subscales of validat-
ed condition-specific questionnaires: the Urinary Distress
Inventory Short Form (UDI-6) and the Urinary Impact
Questionnaire Short Form (UIQ-7).
The primary outcomemeasure was cure, defined objective-
ly and subjectively at 1 year. Objective cure was defined by a
negative standing CST at a volume of 250 ml in the bladder.
Subjective cure was defined by an answer of 0 (no) or 1 (yes,
not bothersome) on question 17 of the Pelvic Floor Distress
Inventory-short form (PFDI-20), which reads, “Do you expe-
rience urine leakage related to coughing/sneezing/laughing?”
Overall cure included the satisfaction of both objective and
subjective criteria; in other words, if a patient did not leak on
the CST, but had a positive answer to question 17 of the PFDI-
20, then she would be considered a failure and vice versa.
Secondary outcome measures included the change in
symptoms and quality of life questionnaires—the Urinary
Distress Inventory (UDI-6) and the Urinary Impact
Questionnaire (UIQ-7) Short Forms—at 1 year. All patients
were evaluated for complications such as cystotomy, mesh
erosion, postoperative pain, need for reoperation, and urinary
retention.
Statistical analysis included descriptive statistics, and
paired Student’s t tests for the questionnaire scores; leak point
pressure and postvoid residual (PVR) values. The Wilcoxon
signed-rank test was used for the pelvic organ prolapse quan-
tification (POP-Q) measures and stages. Statistical signifi-
cance was defined by an alpha value of 0.05.
Results
Between August 2010 and July 2012, 101 patients underwent
the single-incision sling placement at the time of robotic
sacrocolpopexy and were included (Fig. 1). The average age
was 56.5 with an average BMI of 26.5 and a median stage III
prolapse, as listed in Table 1.
One-year follow-up was obtained for 97 out of 101 patients
(96 %). Six patients out of the 97 were only available for
follow-up over the phone. All patients had a positive CST









Fig. 2 Objective cure based on
the cough stress test (CST). All
101 patients at baseline had a
positive CST, while 90 % (n=82)
were cured at 1 year
Table 2 Complications (n=91, objective follow-up; n=97, subjective
follow-up)
Complication Data, % (n)
New onset dyspareunia 1 (1/97)
Intraoperative cystotomy 0 (0/101)
Mesh erosion 0 (0/91)
Urinary retention 0 (0/97)
Sling revision 0 (0/97)
Pain at 1 year 0 (0/97)
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majority (90 out of 101, 89 %) complained of some degree of
SUI at intake. Occult SUI upon reduction of the prolapse was
discovered in only 11 patients (10.8 %) during their preoper-
ative urodynamic testing. Of 101 patients, 100 (99 %) passed
their voiding trial on the first postoperative day and none
presented later with urinary retention. One patient required a
second day for a successful voiding trial in the office. There
were no intraoperative cystotomies, no mesh erosions, no
sling revisions, and no cases of urinary retention as listed in
Table 2. One postmenopausal patient complained of new
onset dyspareunia at the 3-month visit, but this problem
resolved with vaginal estrogen.
Overall cure based on both objective and subjective criteria
was 87% at 1 year. Objective cure based on a negative CSTwas
90 % (82 out of 91). Subjective cure based on the postoperative
PFDI-20 questionnaire was 87 % (85 out of 97; Fig. 2). If the 4
patients who were lost to follow-up, were considered failures
then the success rate would be 84 % (85 out of 101). Out of the
12 patients who were not cured, 8 underwent subsequent anti-
incontinence procedures (6 retropubic slings and 2 periurethral
bulking agents); the remaining 4 did not seek any treatment.
The UDI-6 scores improved from 34.8±25.1 at baseline to
6.7±11.2 at 1 year (p<0.001). Similarly, UIQ-7 scores im-
proved from 21.1±22.8 at baseline to 2.4±8.2 at 1 year
(p<0.001; Fig. 3). Prolapse cure rate at 1 year was 93.4 %
based on the NIH criteria of POP-Q stage 0 or 1. Table 3
includes the POP-Q examination points and prolapse stage
before and 12 months after surgery.
The preoperative baseline LPP on urodynamic testing was
lower in patients who continued to leak (12 out of 97) than those
who were cured (85 out of 97); 74.2 cm H2O (CI 54.4–93.9) vs
102.7 cm H2O (CI 94.1–111.3); p=0.01.
There was no difference in PVR at baseline and at 1 year
(36.1 ml vs 20.8 ml) respectively (p=0.02).
Discussion
This study showed that the addition of the Miniarc Precise®
single-incision suburethral sling at the time of robotic
sacrocolpopexy resulted in a high success rate (87% at 1 year),
without mesh erosions, postoperative vaginal or thigh pain,
hematomas, voiding dysfunction or urinary retention.
The strengths of this study include its prospective nature, a
high follow-up rate (96 %), and the fact that the patients
served as their own controls before and after treatment. The
limitation of this study is the lack of a comparison group. The
surgeries were performed in a high volume center by a
fellowship-trained urogynecologist. Only patients who
Table 3 Pelvic organ prolapse quantification (POP-Q) measurements
and stage, at baseline and 1 year (n=91)










































































Fig. 3 Change in validated
quality of life questionnaires,
including the Urinary Distress
Inventory-short form (UDI-6) and
the Urinary Impact
Questionnaire-short form (UIQ-7)
from baseline to 1 year
postoperatively
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demonstrated stress incontinence prior to surgery received the
treatment.
The fact that 99 % of patients passed their voiding trial on
postoperative day 1 highlights the non-obstructive nature of this
single-incision sling, despite the fact that it is not a “tension-
free” sling. All 6 of the patients who subsequently underwent a
retropubic sling placement because of persistent postoperative
leakage were “dry” at their latest follow-up. The single-incision
sling mesh was not revised at the time of retropubic sling
placement and it did not hinder the procedure or its success rate.
Caution should be taken when applying these results to
patients without prolapse, as they were not included in this
study. The relationship between prolapse and urinary inconti-
nence and their concomitant treatment has been the subject of
many studies. The largest randomized trials (the CARE and
OPUS trials) to address this issue recommended the routine
performance of anti-incontinence procedures at the time of
prolapse repair [3, 4]. Despite this evidence, the debate goes
on and many studies and publications since have called for a
more tailored approach and even offered an online risk calcula-
tor for de novo SUI [13]. In the current study occult SUI was
discovered in 11 patients (10.8 %) on preoperative CST with
prolapse reduction. In The OPUS trial the risk of new onset,
postoperative SUI at 3 months was 71.9 % for patients with
occult SUI if they did not undergo a sling [4]. At our center we
continue to offer a suburethral sling to patients with occult SUI
and discuss with them the risks and benefits of a “prophylactic
sling” vs a “two-stage” approach. As to the choice of sling, the
current study has encouraged some of us to continue to implant
theMiniArc® sling at the time of sacrocolpopexy, especially for
patients with significant preoperative voiding difficulties. We
prefer to use a retropubic sling for patients with intrinsic sphinc-
ter deficiency (ISD) or an LPP≤60 cm H2O.
The 1-year prolapse cure rate of 93.5 % is consistent with
prior publications on robotic sacrocolpopexy [14–16]. This
high success rate is important for the validity of the mini-sling
results, since a recurrent anterior wall prolapse would have
increased the “apparent success rate” of the anti-incontinence
procedure in the same way that preoperative prolapse masks
occult SUI.
In conclusion, the addition of a single-incision suburethral
sling at the time of robotic sacrocolpopexy in women with
SUI resulted in a cure rate of 87 % at 1 year. Future long-term
and comparative studies are needed to further elucidate the
role of the single-incision sling in the treatment of SUI in
patients with and without pelvic organ prolapse.
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